Optimi is a commercial-stage pharmaceutical company manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. $OPTH
Joined April 2021
- Tweets 732
- Following 406
- Followers 870
- Likes 966
292 Photos and videos
Jun 11
Dane Stevens, CEO and Co-Founder of Optimi, comments on the Company’s first export of psilocybin biomass and 5mg capsules from its licensed GPM facility to the United Kingdom. For more info, visit: bit.ly/4uuD51c $OPTH
3
66
Jun 10
$OPTH's first shipment of psilocybin biomass & 5mg capsules supports a planned UK Phase 2 clinical trial. Its ability to supply both from a single GMP facility positions it as a vertically integrated supplier for regulated psychedelic research & medicine. bit.ly/4uuD51c
2
83
Jun 10
Optimi announced its first export of naturally derived psilocybin to the UK in support of a planned Phase 2 clinical trial. The shipment includes psilocybin biomass & finished 5mg capsules. Trial partner & indication to be announced at a later date. bit.ly/4uuD51c $OPTH
1
71
Jun 9
Optimi CEO Dane Stevens joins @SpartanTrading to discuss the Company’s recent NASDAQ listing & other milestones as well as how Optimi is well positioned for future growth in markets like the U.S. as regulatory access develops. Watch here: bit.ly/4ugLUeF $OPTH
1
3
727
Jun 9
Optimi CEO and Co-Founder, Dane Stevens comments on the Company's planned product development of 50mg and 100mg dosages of ibogaine. For more info, visit: bit.ly/4vyl7LZ $OPTH
1
2
143
Jun 8
Optimi is developing its ibogaine product at the Company's wholly owned GMP facility. A recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access. Learn more: bit.ly/4vyl7LZ $OPTH
1
2
107
Jun 8
Optimi has secured naturally derived ibogaine from two sources for its Ibogaine Initiative, in both HCl and freebase form. Development work on the finished drug product is anticipated to commence this summer at the Company's GMP facility. bit.ly/4vyl7LZ $OPTH
1
5
132
Jun 4
A recent executive order aims to accelerate research into psychedelic therapies, potentially helping the U.S. catch up with markets like Australia which became the first country to allow authorized psychiatrists to prescribe #MDMA & #psilocybin. cnb.cx/43I4LEF via @CNBC
2
190
Jun 3
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe. For details: bit.ly/43OISDz $OPTH
1
4
118
Jun 3
Dane Stevens, CEO of Optimi comments on the expansion of psychedelic-assisted therapy access under the updated authorised prescriber framework in Australia. For more info: bit.ly/4dQ5E2N $OPTH
1
116
Jun 2
"Optimi is one of the only companies to take naturally derived psilocybin from biomass to a finished drug product, entirely under one roof and on our own licence.” - Dane Stevens on $OPTH's completed GMP production run of its 5mg psilocybin drug product. bit.ly/43OISDz
3
6
208
Jun 2
Optimi announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The finished psilocybin capsules use the same formulation already prescribed to patients in Australia for treatment-resistant depression. Learn more: bit.ly/4eg4tLg $OPTH
4
184
May 29
The recent updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA. More info: bit.ly/4dQ5E2N $OPTH
1
1
78
May 29
Under the AP scheme, psychiatrists may prescribe Optimi’s #MDMA for PTSD & #psilocybin for treatment-resistant depression, making Australia the first country in the world to recognise & regulate both substances as medicines for these indications. bit.ly/4dQ5E2N $OPTH
2
128
May 29
Optimi has acknowledged the final recommendations published by Australia's Therapeutic Goods Administration (TGA) following its targeted consultation on the Authorised Prescriber (AP) scheme for psilocybin and MDMA. Learn more: bit.ly/4fOAdZ8 $OPTH
1
5
138
May 26
A portion of Optimi's newly completed extract has been earmarked to support upcoming clinical research programs in Europe, where the Company is expected to supply GMP-grade finished material into sponsor-led studies. bit.ly/43tF9ev $OPTH
3
84
May 26
Optimi has completed a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, the highest-purity botanical extract produced by the Company to date. bit.ly/43tF9ev $OPTH
1
4
92
May 20
Optimi has announced the pricing of its underwritten public offering in connection with the uplisting of its common shares to the Nasdaq Capital Market. The shares are expected to begin trading on the Nasdaq Capital Market on May 20 under the symbol $OPTH. bit.ly/3PNOwTf
1
180
May 19
Reuters: Trump's psychedelic EO has investors calling — $OPTI CEO Dane Stevens confirmed his company fielded calls almost immediately after the order dropped. $OPTHF manufactures GMP-certified pharmaceutical psilocybin & MDMA for regulated markets today.
reuters.com/business/healthc…
1
2
345
May 14
Analysts say GMP-certified psilocybin manufacturing is one of the sector's biggest barriers to entry. $OPTI has already cleared that bar; Health Canada-licensed, GMP-certified, actively supplying regulated markets today.
shroomfan.com/health-wellnes…
#Psilocybin #GMP $OPTHF
1
2
345